Original Research

Aluminum Chloride Hexahydrate in a Salicylic Acid Gel Base: A Case Series of Combination Therapy With Botulinum Toxic Type A for Moderate to Severe Hyperhidrosis

Author and Disclosure Information

Hyperhidrosis is a common condition that has a tremendous impact on the quality of life of patients. For moderate to severe hyperhidrosis, topical aluminum chloride hexahydrate (AC), iontophoresis, and botulinum toxin type A injections are first-line therapies. Botulinum toxin type A has been a useful addition to the hyperhidrosis armamentarium and typically is utilized when topical therapy or iontophoresis have failed. Although highly effective for most patients, there remains a subset of patients who do not completely respond to botulinum toxin type A injections. For these patients, combination therapy with AC can greatly improve patient response. We present a case series of 10 patients with hyperhidrosis and a history of partial response to botulinum toxin type A monotherapy. With the addition of AC 15% in a salicylic acid 2% gel base, 5 patients achieved 75% to 100% reduction in sweating and 5 patients achieved 100% reduction in sweating. Aluminum chloride hexahydrate in a salicylic acid gel base offers a novel and effective topical therapy in combination with botulinum toxin type A for patients with moderate to severe hyperhidrosis.


 

Recommended Reading

AMA House Ends on a Sour Note: The Policy & Practice Podcast
MDedge Dermatology
IPAB, Medicaid Block Grants Addressed by AMA House
MDedge Dermatology
Only One in Four Women Equate Beauty With Youth
MDedge Dermatology
FDA: Nature Relief's Instant Wart and Mole Remover Recalled
MDedge Dermatology
Rolling Out Health Reform: The Policy & Practice Podcast
MDedge Dermatology
Newly Approved Filler Uses Patient's Own Cells
MDedge Dermatology
Physicians Need Training on Handling Stalkers
MDedge Dermatology
Bimatoprost Repigments Vitiligo Patient Skin
MDedge Dermatology
Appeals Court Ruling Upholds Individual Mandate
MDedge Dermatology
Topical Combo Shows Early Promise in Moderate Psoriasis
MDedge Dermatology